Understanding how amyloid interactions shape Alzheimer’s disease vulnerability
Official title: Heterotypic amyloid interactions as modulators of selective cellular vulnerability
Funded at Flanders Interuniv Inst Biotechnology · NIH-11332577 · Data updated 2026-11-12
A patient-friendly look at a study exploring how amyloid plaques in the brain interact with other proteins to influence where Alzheimer’s disease starts and progresses, with potential implications for new treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Flanders Interuniv Inst Biotechnology NIH-funded |
| Lab location | 1 site (Gent, Belgium) |
| Project start | September 30, 2022 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $481,531 |
| NIH project number | 5R01AG079234-05 |
| Project ID | NIH-11332577 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable to patient recruitment in this basic science grant; future translational efforts may interest individuals with Alzheimer’s disease.
✕Less likely to help
This project does not involve direct patient participation and does not yet offer a treatment option.
What this research studies
This project investigates how amyloid plaques formed by beta-amyloid and tau proteins interact with other proteins in the brain. By mapping these interactions, researchers hope to uncover why certain brain areas become vulnerable in Alzheimer’s disease. The work uses proteomic and structural approaches to identify partners that influence plaque formation and disease progression. Findings could guide the development of therapies that target these interactions to slow or alter the course of the disease. Participants would not be required to take part in this basic science project, but future translational work could bring new options to patients with Alzheimer’s disease.
Why it matters
Potential benefit: If successful, the research could identify new targets for therapies that modify amyloid aggregation and neuronal vulnerability in Alzheimer’s disease.
How similar studies have gone: Proteomic studies have shown multiple proteins co-depose with amyloid, and this work aims to extend understanding by linking specific interactions to disease vulnerability.
Where this research is happening
-
Flanders Interuniv Inst Biotechnology
Gent, Belgium Active
Researchers
- Principal investigator: Schymkowitz, Joost — Flanders Interuniv Inst Biotechnology
- Study coordinator: Schymkowitz, Joost
Related research
Other NIH-funded projects on the same topics.
-
TMEM106B, GRN, and TDP-43: exploring human samples and models to understand FTLD-TDP biology
A study to understand how TDP-43-related brain changes cause FTLD-TDP by using human samples and human-like models to uncover disease mechanisms that could inform future treatments.
-
How TMEM106B, GRN and TDP-43 interact in frontotemporal dementia
Looking at how three proteins—TMEM106B, progranulin (GRN), and TDP-43—work together to better understand frontotemporal dementia in people who develop early-onset dementia.
-
Investigating how amyloid proteins interact and affect brain cells in Alzheimer's disease
This study is looking at how certain proteins related to Alzheimer's disease clump together in the brain and how they interact with other proteins, which could help us understand the disease better and find new ways to treat it.
-
Identifying markers to predict which ductal carcinoma in situ may become invasive
This study is looking at a type of non-invasive breast cancer called DCIS to find clues that can help doctors know which cases might turn into more serious cancer, so they can create better, more personalized treatment plans for patients.
-
Investigating the mechanisms of frontotemporal lobar degeneration using human samples and models
This study is looking at how certain proteins and genes affect frontotemporal lobar degeneration (FTLD), a type of dementia that impacts younger people, to help find better ways to diagnose and treat the condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.